In:
Revista de Chimie, Revista de Chimie SRL, Vol. 70, No. 8 ( 2019-9-15), p. 2791-2794
Abstract:
The immune system could mediate the antitumor activity of several anticancer treatments. Several chemotherapy compounds, including anthracyclines and oxaliplatin, induce immunogenic cell death that in turn activates the antitumor immune response. Trastuzumab induces antibody-dependant cell-mediated cytotoxicity. On the basis of this background, immune markers have recently been the focus of intense translational research to predict and monitor the efficacy of treatments. Gene expression arrays and immunohistochemistry have assessed immune activation and infiltration by macrophages, natural killer, and T and B lymphocytes. In this paper we present the results of a study that included 22 patients diagnosed with Her2 positive breast cancer undergoing treatment with Transtuzumab.
Type of Medium:
Online Resource
ISSN:
0034-7752
,
2668-8212
DOI:
10.37358/RC.19.8.7428
Language:
English
Publisher:
Revista de Chimie SRL
Publication Date:
2019
detail.hit.zdb_id:
2488208-2
Bookmarklink
